Inhibrx Biosciences (INBX) Leases (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Leases for 3 consecutive years, with $5.5 million as the latest value for Q4 2025.
- Quarterly Leases fell 24.57% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, down 24.57% year-over-year, with the annual reading at $5.5 million for FY2025, 24.57% down from the prior year.
- Leases for Q4 2025 was $5.5 million at Inhibrx Biosciences, down from $6.0 million in the prior quarter.
- The five-year high for Leases was $7.3 million in Q4 2024, with the low at $1.5 million in Q3 2024.
- Average Leases over 3 years is $4.8 million, with a median of $5.8 million recorded in 2025.
- Peak annual rise in Leases hit 293.7% in 2025, while the deepest fall reached 24.57% in 2025.
- Over 3 years, Leases stood at $3.0 million in 2023, then soared by 148.58% to $7.3 million in 2024, then fell by 24.57% to $5.5 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $5.5 million, $6.0 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.